AbolerIS Pharma is a Belgian biopharmaceutical company focused on immunotherapies for autoimmune and inflammatory diseases. Its lead program is a monoclonal antibody that targets the novel receptor CD45RC with the goal of restoring immune tolerance. The company aims for durable remissions and therapies with fewer side effects compared with current immunosuppressive options. Cofounders Dr. Ignacio Anegon and Dr. Carole Guillonneau and a team of experienced immunology scientists lead the research. The financing announced will be used to accelerate the clinical development of the antibody and advance it toward becoming a potential new treatment standard for conditions such as rheumatoid arthritis.

Total raised

$29M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2023